Adjuvant Aflibercept for Metastatic Colorectal Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

January 31, 2016

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Aflibercept

Aflibercept: 4mg/kg IV q2weeks until progression for a maximum of 2 years

Trial Locations (2)

02903

Rhode Island Hospital (East Greenwich and Newport), Providence

The Miriam Hospital, Providence

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Rhode Island Hospital

OTHER

collaborator

The Miriam Hospital

OTHER

collaborator

Lifespan

OTHER

collaborator

University of California, San Diego

OTHER

collaborator

Montefiore Medical Center

OTHER

collaborator

University of Florida

OTHER

collaborator

Sanofi

INDUSTRY

lead

Brown University

OTHER

NCT01669720 - Adjuvant Aflibercept for Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter